Palmar plantar erythrodysesthesia differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
Line 14: | Line 14: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Additional diagnostic clues | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Additional diagnostic clues | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | Palmar plantar erythrodysesthesia | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | The areas of well-defined intense erythema and edema | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* A variable degree of epidermal (keratinocytes) necrosis | * A variable degree of epidermal (keratinocytes) necrosis | ||
* Vacuolar degeneration of the basal cell layer of epidermis | * Vacuolar degeneration of the basal cell layer of epidermis | ||
Line 26: | Line 26: | ||
* Neutrophilic eccrine hidradenitis | * Neutrophilic eccrine hidradenitis | ||
* Eccrine squamous syringometaplasia, in severe PPE (WHO grades 3 and 4) | * Eccrine squamous syringometaplasia, in severe PPE (WHO grades 3 and 4) | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | History of chemotherapeutic agent use | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4 | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4 | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4 | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4 | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x1 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x2 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x3 | ||
| style="background: #DCDCDC; padding: 5px; text-align: | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | x4 | ||
|- | |- | ||
|} | |} |
Revision as of 23:05, 30 July 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
PPE must be differentiated from Graft-Versus-Host Disease (GVHD).
Differentiating palmar plantar erythrodysesthesia from other Diseases
Disease | Clinical manifestation | Histopathology | Additional diagnostic clues |
---|---|---|---|
Palmar plantar erythrodysesthesia | The areas of well-defined intense erythema and edema |
|
History of chemotherapeutic agent use |
x1 | x2 | x3 | x4 |
x1 | x2 | x3 | x4 |
x1 | x2 | x3 | x4 |
x1 | x2 | x3 | x4 |
x1 | x2 | x3 | x4 |